Skip to content
  • About
    • Oncolytic Viruses
    • Immunotherapy Combinations
    • R&D Facility
    • Team
    • Company News
    • Corporate Investor Deck
  • Leadership Team
    • Board
    • Management Team
  • Our Technology
    • IVX037
    • IVX055
    • Pipeline
    • Scientific Presentations
    • Pre-clinical / discovery
  • Clinical
    • Therapeutic Strategy
    • Innovent Collaboration
    • Pipeline
  • Investor Centre
    • Corporate Deck
    • Company Announcements
    • In the News
    • ESG
  • Recruitment
  • Contact
Menu
  • About
    • Oncolytic Viruses
    • Immunotherapy Combinations
    • R&D Facility
    • Team
    • Company News
    • Corporate Investor Deck
  • Leadership Team
    • Board
    • Management Team
  • Our Technology
    • IVX037
    • IVX055
    • Pipeline
    • Scientific Presentations
    • Pre-clinical / discovery
  • Clinical
    • Therapeutic Strategy
    • Innovent Collaboration
    • Pipeline
  • Investor Centre
    • Corporate Deck
    • Company Announcements
    • In the News
    • ESG
  • Recruitment
  • Contact

Department: Board

Dr Jeannie Joughin

Jeannie Joughlin

Mr Robert Routley

Robert Routley

Dr Leonard Post

Dr Leonard Post

Prof. Darren Shafren

Prof. Darren Shafren

Dr Malcolm McColl

Malcolm McColl

Join Our Mailing List

Our mission is to develop receptor targeted, oncolytic RNA immunotherapies to provide durable responses and high quality of life in patients with some of the most globally prevalent cancers

About Us
Our Technology
Immvirx logo

A clinical stage company developing receptor targeted oncolytic RNA immunotherapies to enable powerful and durable responses in the most globally prevalent cancers with high unmet need.

Twitter Linkedin
Company
  • About
    • Oncolytic Viruses
    • Immunotherapy Combinations
    • R&D Facility
    • Team
    • Company News
    • Corporate Investor Deck
  • Leadership Team
    • Board
    • Management Team
  • Our Technology
    • IVX037
    • IVX055
    • Pipeline
    • Scientific Presentations
    • Pre-clinical / discovery
  • Clinical
    • Therapeutic Strategy
    • Innovent Collaboration
    • Pipeline
  • Investor Centre
    • Corporate Deck
    • Company Announcements
    • In the News
    • ESG
  • Recruitment
  • Contact
  • About
    • Oncolytic Viruses
    • Immunotherapy Combinations
    • R&D Facility
    • Team
    • Company News
    • Corporate Investor Deck
  • Leadership Team
    • Board
    • Management Team
  • Our Technology
    • IVX037
    • IVX055
    • Pipeline
    • Scientific Presentations
    • Pre-clinical / discovery
  • Clinical
    • Therapeutic Strategy
    • Innovent Collaboration
    • Pipeline
  • Investor Centre
    • Corporate Deck
    • Company Announcements
    • In the News
    • ESG
  • Recruitment
  • Contact
© 2024 ImmVirX Pty Ltd • Site by Noise